Vor Biopharma to Present at the Barclays Global Healthcare Conference
Vor Biopharma (Nasdaq: VOR), a leader in engineered hematopoietic stem cell therapies, announced its participation in the Barclays Global Healthcare Conference, set for March 9-11, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Biopharma (Nasdaq: VOR), a leader in engineered hematopoietic stem cell therapies, announced its participation in the Barclays Global Healthcare Conference, set for March 9-11, 2021. CEO Robert Ang and CFO Nathan Jorgensen will present on March 11 at 3:00 p.m. E.T. Interested parties can access the live webcast through the Investors section of Vor's website. Vor Biopharma is dedicated to innovating cancer treatments, focusing on creating treatment-resistant transplants that enhance targeted therapies while protecting healthy cells.
Details
News Market Reaction – VOR
The recorded move for VOR in the trading session of this news was -0.98%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Barclays Global Healthcare Conference, which will take place virtually on March 9-11, 2021.
Robert Ang, MBBS, MBA, Vor’s President and Chief Executive Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are scheduled to present on Thursday, March 11, 2021, at 3:00 p.m. E.T. A live webcast of the presentation can be accessed via the Investors section of the Company's website at www.vorbio.com. An archived replay of the webcast will be available on the Company's website following the conference.
About Vor Biopharma
Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.
Contacts:
Investor:
Constantine Davides, CFA
Westwicke
+1 339-970-2846
constantine.davides@westwicke.com
Media:
Mary Carmichael
Ten Bridge Communications
+1 617-413-3543
mary@tenbridgecommunications.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.